<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00662740</url>
  </required_header>
  <id_info>
    <org_study_id>1184.14</org_study_id>
    <secondary_id>2007-005134-36</secondary_id>
    <nct_id>NCT00662740</nct_id>
  </id_info>
  <brief_title>Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol PE Capsule) in COPD</brief_title>
  <official_title>1-yr Study Comparing TioSal Combo Regimens Versus Single Agent Therapies (Spiriva HandiHaler and Salmeterol PE Capsule)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to assess bronchodilator efficacy as determined by
      FEV1, the effect on dyspnoea as determined by the BDI/TDI, the effect on health status as
      determined by the SGRQ and the effect on COPD exacerbations.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>April 2008</start_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trough FEV1 response</measure>
    <time_frame>12 Weeks, 24 Weeks and 48 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>FEV1AUC 0 8h response</measure>
    <time_frame>12 Weeks, 24 Weeks and 48 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mahler TDI focal score</measure>
    <time_frame>12 Weeks, 24 Weeks and 48 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>SGRQ total score</measure>
    <time_frame>12 Weeks, 24 Weeks and 48 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to first moderate to severe COPD exacerbation</measure>
    <time_frame>12 Weeks, 24 Weeks and 48 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC0-8h response</measure>
    <time_frame>4, 36 and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 response</measure>
    <time_frame>4, 36 and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 response</measure>
    <time_frame>12, 24, 36 and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of rescue medication (weekly mean number of puffs of as-needed salbutamol/albuterol per day, daytime and night-time)</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC (forced vital capacity) AUC0-8h and trough FVC response</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual FEV1, FVC and PEF measurements</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly mean morning pre-dose and evening pre-dose PEFs (peak expiratory flow) and FEV1 (recorded by AM2+); PEFs determined by spirometry ]</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly mean number of COPD related night time awakenings</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mahler TDI focal score</measure>
    <time_frame>4, 36 and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mahler Dyspnoea Indices (Functional Impairment, Magnitude of Task and Magnitude of Effort)</measure>
    <time_frame>4, 12, 24, 36 and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SGRQ total score, and the impact, activity and symptoms domain scores from the SGRQ</measure>
    <time_frame>4, 12, 36 and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All adverse events</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs: pulse rate and blood pressure</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Routine blood chemistry, haematology and urinalysis</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital status of randomised patients</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days in hospital (including ambulance transportation</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of unscheduled health care provider visits</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of visits in emergency room (including ambulance transportation)</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days in intensive care unit</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concomitant medications (for instance antibiotics and systemic steroids).</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Tiotropium/Salmeterol QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tiotropium Inhalation Powder, hard gelatine capsule (Spiriva®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salmeterol BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Salmeterol Inhalation Powder, hard PE capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium/Salmeterol QD+ Salmeterol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule, plus Salmeterol Inhalation Powder, hard PE capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium/Salmeterol QD</intervention_name>
    <description>Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule</description>
    <arm_group_label>Tiotropium/Salmeterol QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salmeterol</intervention_name>
    <description>Salmeterol Inhalation Powder, hard PE capsule</description>
    <arm_group_label>Salmeterol BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium/Salmeterol QD+ Salmeterol</intervention_name>
    <description>Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule, plus Salmeterol Inhalation Powder, hard PE capsule</description>
    <arm_group_label>Tiotropium/Salmeterol QD+ Salmeterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
    <description>Tiotropium</description>
    <arm_group_label>Tiotropium QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Main:

        Diagnosis of COPD Post-bronchodilator FEV1&lt;80% predicted and FEV1/FVC&lt;70% predicted

        Exclusion criteria:

        Main:

        Significant other diseases then COPD Recent MI Unstable or life-threatening arrythmia
        requiring intervention or change in drug therapy Hospitalisation for cardiac failure in
        past year History of asthma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1184.14.01013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.01018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.01006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.01003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coeur D'Alene</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.01015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.01007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.01005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.01020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.01009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.01002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.01021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.01012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.01017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.01008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.01014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.01022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Killeen</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.01001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.01010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.01011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.01019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.43001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Feldbach</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.32001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.32004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Turnhout</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.02005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.02003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chilliwack</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.02010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.02001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Niagara Falls</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.02002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Malbaie</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.02008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ste-Foy</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.02007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.45001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.45002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>København NV</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.37202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tallin</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.37201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.35802 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Espoo</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.35801 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>HUS</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.3301A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.3304A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.3302A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.3303A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.3303B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.3303C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.49006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.49008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.30001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.30004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nafplio</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.30006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rethymno</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.36002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.36001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hodmezövasarhely</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.36005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Komlo</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.36004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.39001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.82001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.82002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.82003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.37101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kraslava</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.37103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kuldiga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.37102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Talsi</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.37003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Klaipeda</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.31004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.31003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.31002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.31001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Veldhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.42103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bardejov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.46002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.46001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1184.14.46003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sundsvall</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>Slovakia</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Croatia</country>
    <country>Mexico</country>
    <country>Norway</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>Ukraine</country>
  </removed_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2008</study_first_submitted>
  <study_first_submitted_qc>April 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2008</study_first_posted>
  <disposition_first_submitted>April 30, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>April 30, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 16, 2014</disposition_first_posted>
  <last_update_submitted>April 30, 2014</last_update_submitted>
  <last_update_submitted_qc>April 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

